Project Grant R01HL176497
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$651K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The 5-year grant, which commenced on May 15, 2025, supports research by Dr. Joshua Meisner, a pediatric cardiologist and physician-scientist, to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy (HCM) caused by MYBPC3 gene mutations. The research aims to develop...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $159,512 to The Leland Stanford Junior University to investigate strategies for mitigating cardiac fibrosis, a key contributor to dilated cardiomyopathy (DCM). The research aims to validate two candidate compounds identified in a prior drug screen, CGS15943 and AM404, using advanced techniques like 3D cardiac organoids and a mouse DCM...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to identify new therapeutic targets for dilated cardiomyopathy (DCM), a leading cause of heart failure. The $248,999 award to the University of California, San Diego aims to study the role of microRNAs in regulating sarcomeric and contractile functions in DCM, with the goal of developing mechanism-based therapeutic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512 to The Leland Stanford Junior University to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy (DCM). The research utilizes induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carrying DCM mutations to study the cellular and molecular mechanisms by which impaired proteostasis leads to cardiac dysfunction in...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $100,480 to The University of Texas Southwestern Medical Center to conduct research on understanding the roles of nuclear envelope proteins and DNA damage in cardiomyopathy. The key objectives of this 2-year research project are to: 1) characterize the DNA damage and DNA damage response in cardiomyocytes carrying LEMD2 mutations...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $194,375 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, Santa Barbara (UCSB) to study the impact of cardiomyopathy-driven extracellular matrix (ECM) remodeling on myocardial viscoelasticity and its effects on cardiomyocyte phenotype. The 24-month project aims to: 1) Determine how cardiomyopathy alters myocardial viscoelasticity, and 2) Assess how matrix viscoelasticity regulates...